 Home > Medical News > Latest Medical News > Recombinant humanized anti-HER2-ADC for injection approved by Zhejiang Pharmaceutical Subsidiary

Recombinant humanized anti-HER2-ADC for injection approved by Zhejiang Pharmaceutical Subsidiary

 Last Update: 2022-05-17
 Source: Internet
 Author: User

Tags

morphine drug class

ovarian cancer dogs

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On April 22, Zhejiang Pharmaceutical announced that its subsidiary, Xinma Bio, received the approval and issuance of the recombinant humanized anti-HER2 monoclonal antibody-AS269 conjugate for injection (ARX788) (referred to as "anti-HER2") approved and issued by the State Food and Drug Administration.

Recombinant humanized anti-HER2 monoclonal antibody-AS269 conjugate for injection (ARX788) is a new generation of monoclonal antibody conjugated drug jointly developed by the company and Ambrx in the United States on June 14, 2013.

The company launched a phase I clinical study of ARX788 monotherapy in HER2-positive advanced breast cancer in 2017.

In 2019, the company launched a phase I clinical study of ARX788 in the treatment of patients with HER2-positive advanced metastatic gastric cancer and gastroesophageal junction adenocarcinoma.

As of March 31, 2022, the company's ARX788 project has invested a total of 555 million yuan in research and development expenses

At present, HER2-targeting drugs that have been marketed at home and abroad include trastuzumab (original research by Roche, trade name Herceptin, with sales of CHF 2.

According to EVALUATEPHARMA, the global sales of the HER2-targeted anti-tumor market reached US$11.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.